Mental health · Illinois
Mental health studies in Illinois
71 studies have at least one recruiting site in Illinois. Mental health research includes studies of depression, anxiety, PTSD, bipolar disorder, schizophrenia and ADHD, testing medicines, devices and talk therapies.
71 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Chicago, IL + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Naperville, IL + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Chicago, IL + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Chicago, IL + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Chicago, IL + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Evanston, IL + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Tonix Pharmaceuticals, Inc.
- Location
- Chicago, IL + 25 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC
- Location
- Skokie, IL + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Chicago, IL + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Reunion Neuroscience Inc
- Location
- Chicago, IL + 26 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
- Location
- Naperville, IL + 18 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Device for Treating Generalized Anxiety
BTL Industries Ltd.
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
- Location
- Chicago, IL + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Brexanolone Lifting Outcomes Of Moms
Lipocine Inc.
- Location
- Chicago, IL + 15 other US sites
- Eligibility basics
- Ages 15–45 · Women only
- RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bristol-Myers Squibb
- Location
- Chicago, IL + 39 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc.
- Location
- Chicago, IL + 22 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Bristol-Myers Squibb
- Location
- Chicago, IL + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Chicago, IL + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Chicago, IL + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Novartis Pharmaceuticals
- Location
- Chicago, IL + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie
- Location
- Orland Park, IL + 30 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences, Inc
- Location
- Chicago, IL + 22 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc.
- Location
- Chicago, IL + 12 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
LB Pharmaceuticals Inc.
- Location
- Chicago, IL + 25 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Will joining affect my current treatment?
Some studies require changes to medicines, which the study team manages; others add to your usual care. Talk to your own clinician before making any change.